Study to Assess the Efficacy, Safety, and Tolerability of the BITE® Antibody Blinatumomab in Adult Subjects with Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia

Sponsor ID

MT103-203

Clinicaltrials.gov ID

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

Phase

Phase 2

Product

blinatumomab

Type

Interventional

Masking

N/A

Enrollment

N/A

Additional Study Details

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Study Synopsis

Available Language(s): English

No locations found.